Lung Microphysiological System Validates Novel Cell Therapy for Acute Respiratory Distress Syndrome

Area of Science:

• Regenerative Medicine
• Pulmonary Medicine
• Stem Cell Biology

Background:

• Acute Respiratory Distress Syndrome (ARDS) is a critical condition with high mortality.
• Current treatments like Dexamethasone have significant side effects.
• There is a need for safer and more effective ARDS therapies.

Purpose of the Study:

• To evaluate the therapeutic potential of primed human umbilical cord blood-derived mesenchymal stem cells (hUCB-pMSCs) for ARDS.
• To compare hUCB-pMSCs efficacy against Dexamethasone in an ARDS model.
• To investigate the mechanisms underlying hUCB-pMSCs' effects on lung tissue.

Main Methods:

• Development of a novel lung microphysiological system (MPS) to simulate ARDS.
• Treatment of the ARDS model with hUCB-pMSCs and Dexamethasone.
• Analysis using fluorescence-based imaging and single-cell RNA sequencing.

Main Results:

• hUCB-pMSCs significantly activated angiogenesis-related pathways in endothelial cells.
• Enhanced formation of tip-like endothelial cells, crucial for new blood vessel growth.
• Fluorescence microscopy confirmed the pro-angiogenic effects of hUCB-pMSCs.

Conclusions:

• hUCB-pMSCs demonstrate significant potential as a therapeutic agent for ARDS.
• The study supports hUCB-pMSCs as a promising alternative to existing treatments.
• hUCB-pMSCs promote vascular repair mechanisms relevant to ARDS treatment.